# Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct02453282/  
OnCo record `nct02453282` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT02453282 by AstraZeneca, with 1118 participants enrolled, started 2015-07-21 and due to reach its primary completion in 2018-10-04. Interventions recorded: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin and Pemetrexed + Cisplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: MYSTIC
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02453282
- Phase: 3
- Setting: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
- Sponsor: AstraZeneca
- Enrolled: 1118
- Outcomes: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy: Durvalumab Monotherapy 16.3 months vs Durvalumab + Tremelimumab 11.9 months vs SoC Chemotherapy 12.9 months; Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy: Durvalumab + Tremelimumab 3.9 months vs SoC Chemotherapy 5.4 months, HR 1.05; Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population: Durvalumab Monotherapy 35.6% vs Durvalumab + Tremelimumab 34.4% vs SoC Chemotherapy 37.7%

## Sources

- ClinicalTrials.gov NCT02453282: https://clinicaltrials.gov/study/NCT02453282

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct02453282-jama-oncol-2020/)
- terms: [Lung cancer: the failed and stopped programmes, and why](https://onco.cc/terms/lung-failed-programmes/)
- trials: [Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).](https://onco.cc/trials/nct03164616/)

---
JSON: https://onco.cc/api/v1/entities/nct02453282.json